Galapagos (ADR) (GLPG)
Belgian biotech shifting from cell therapy toward partnered immunology and oncology assets.
$27.98
vs last close+0.47 (+1.71%)
No recent trading data
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 48.65% | 32.06M ADS | |
|---|---|---|---|
| 79 holders · as of Jun 30, 2026 | |||
| Other | 51.35% | 33.84M ADS | |
| remainder | |||
65.90M ADS as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
79 holders · 32.06M shares · 10 new positions · 36 increased · 28 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 16.71M | 25.35% | 0 | Aug 3, 2026 |
| Tang Capital Management LLC | 3.79M | 5.75% | 0 | Aug 14, 2026 |
| Madison Avenue Partners, LP | 3.45M | 5.23% | +982.6K | Aug 14, 2026 |
| Prosight Management, LP | 2.04M | 3.10% | +493.3K | Aug 14, 2026 |
| Ecor1 Capital, LLC | 1.67M | 2.53% | 0 | Aug 14, 2026 |
| Ameriprise Financial Inc | 1.27M | 1.93% | −152.4K | Aug 14, 2026 |
| Dme Capital Management, LP | 482.7K | 0.73% | 0 | Aug 14, 2026 |
| Renaissance Technologies LLC | 407.8K | 0.62% | +92.4K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Gilead Sciences, Inc. | 29.90% | 20.98M | 13D | Jan 10, 2025 |
| EcoR1 Capital, LLCincl. EcoR1 Capital Fund, L.P., EcoR1 Capital Fund Qualified, L.P. +1 more | 13.22% | 8.71M | 13D | Jul 28, 2025 |
| Tang Capital Management, LLC | 8.40% | 5.56M | 13G | Oct 29, 2025 |
| Madison Avenue International LP | 5.50% | 3.61M | 13G | Jun 23, 2026 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.